Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice
- 1 February 2017
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 91 (3)
Abstract
Despite success in viral inhibition and CD4 T cell recovery by highly active antiretroviral treatment (HAART), HIV-1 is still not curable due to the persistence of the HIV-1 reservoir during treatment. One patient with acute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from a homozygous CCR5 Δ32 donor has had no detectable viremia for 9 years after HAART cessation. This case has inspired a field of HIV-1 cure research focusing on engineering HIV-1 resistance in permissive cells. Here, we employed a glycosylphosphatidylinositol (GPI)-scFv X5 approach to confer resistance of human primary CD4 T cells to HIV-1. We showed that primary CD4 T cells expressing GPI-scFv X5 were resistant to CCR5 (R5)-, CXCR4 (X4)-, and dual-tropic HIV-1 and had a survival advantage compared to control cells ex vivo . In a hu-PBL mouse study, GPI-scFv X5-transduced CD4 T cells were selected in peripheral blood and lymphoid tissues upon HIV-1 infection. Finally, GPI-scFv X5-transduced CD4 T cells, after being cotransfused with HIV-infected cells, showed significantly reduced viral loads and viral RNA copy numbers relative to CD4 cells in hu-PBL mice compared to mice with GPI-scFv AB65-transduced CD4 T cells. We conclude that GPI-scFv X5-modified CD4 T cells could potentially be used as a genetic intervention against both R5- and X4-tropic HIV-1 infections. IMPORTANCE Blocking of HIV-1 entry is one of most promising approaches for therapy. Genetic disruption of the HIV-1 coreceptor CCR5 by nucleases in T cells is under 2 clinical trials and leads to reduced viremia in patients. However, the emergence of viruses using the CXCR4 coreceptor is a concern for therapies applying single-coreceptor disruption. Here, we report that HIV-1-permissive CD4 T cells engineered with GPI-scFv X5 are resistant to R5-, X4-, or dual-tropic virus infection ex vivo . In a preclinical study using hu-PBL mice, we show that CD4 T cells were protected and that GPI-scFv X5-transduced cells were selected in HIV-1-infected animals. Moreover, we show that GPI-scFv X5-transduced CD4 T cells exerted a negative effect on virus replication in vivo . We conclude that GPI-scFv X5-modified CD4 T cells could potentially be used as a genetic intervention against both R5- and X4-tropic HIV-1 infections.Keywords
Funding Information
- Chinese National Science Fundation (31170871)
- National Science and Technology Major Project (2014ZX10001-001)
- NIH-CNSF joint grant (81361120406)
- HHS | National Institutes of Health (AI095097, R01AI080432)
- China Scholarship Council (201504910661)
This publication has 60 references indexed in Scilit:
- CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activityNucleic Acids Research, 2013
- Genomic Editing of the HIV-1 Coreceptor CCR5 in Adult Hematopoietic Stem and Progenitor Cells Using Zinc Finger NucleasesMolecular Therapy, 2013
- Zinc-finger Nuclease Editing of Human cxcr4 Promotes HIV-1 CD4+ T Cell Resistance and EnrichmentMolecular Therapy, 2012
- Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selectionNature Methods, 2011
- A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicityNucleic Acids Research, 2011
- Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivoNature Biotechnology, 2010
- RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34 + Cells in Patients Undergoing Transplantation for AIDS-Related LymphomaScience Translational Medicine, 2010
- Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesNature Biotechnology, 2008
- Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptidesGene Therapy, 2008
- Treatment for Adult HIV InfectionJAMA, 2004